Healthcare / Medical Instruments & SuppliesShenzhen
$6.87
+0.12 (+1.72%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 18%
FCF escenarios
weak_data · normalized FCF $36.2M · quality 45.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
36/100
D
Piotroski
8/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$2.1B
P/E
76.3x
↑EV/EBITDA
32.2x
↑ROE
2.3%
↑Gross Margin
43.0%
↓Debt/Equity
0.25
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
-11.9%
FCF CAGR
—
FCF margin
17.6%
FCF / Net income
5.90x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $486.3M · net income $14.5M · FCF $85.8M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $486.3M | $486.3M | $581.3M | $644.6M | $710.8M |
| Net Income | $14.5M | $14.5M | $-117.9M | $-63.2M | $-198.3M |
| EBITDA | $61.8M | $61.8M | $-69.4M | $18.6M | $-147.8M |
| EPS | 0.05 | 0.05 | -0.38 | -0.20 | -0.64 |
| Gross Margin | 43.0% | 43.0% | 41.4% | 39.8% | 37.2% |
| Operating Margin | 8.6% | 8.6% | 4.2% | -0.6% | -2.3% |
| Net Margin | 3.0% | 3.0% | -20.3% | -9.8% | -27.9% |
| Balance Sheet | |||||
| Debt/Equity | 0.25 | 0.25 | 0.58 | 0.55 | 0.54 |
| Current Ratio | 1.46 | 1.46 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $85.8M | $85.8M | $30.6M | $36.2M | $-15.6M |
| Returns | |||||
| ROE | 2.3% | 2.3% | -19.4% | -8.7% | -25.3% |
| Valuation | |||||
| P/E | 76.33 | 76.33 | — | — | — |
| EV/EBITDA | 32.19 | 32.19 | — | 140.59 | — |
| P/B | 3.22 | 3.22 | 2.77 | 3.37 | 2.68 |
| Growth & Yield | |||||
| Revenue Growth | -16.4% | -16.4% | -9.8% | -9.3% | — |
| EPS Growth | 113.2% | 113.2% | -90.0% | 68.8% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
130.2%
EPS terminal req.
$0.61
Spread vs growth
-17.0%
5Y implied EPS CAGR
71.3%
EPS terminal req.
$0.74
Spread vs growth
41.9%
10Y implied EPS CAGR
37.3%
EPS terminal req.
$1.19
Spread vs growth
75.9%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+13.4%
Start / end P/E
n/dx → n/dx
EPS bridge
-0.38 → 0.05
Residual
+13.4%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.